HKEX Filings
-
Mar 29, 2023
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2022
-
Mar 16, 2023DATE OF BOARD MEETING
-
Mar 3, 2023Monthly Return of Equity Issuer on Movements in Securities for the Month ended February 28, 2023
-
Feb 20, 2023INSIDE INFORMATION - CLOVER ENTERS INTO EXCLUSIVE AGREEMENT TO COMMERCIALIZE QUADRIVALENT SEASONAL INFLUENZA VACCINE IN MAINLAND CHINA
-
Feb 14, 2023VOLUNTARY ANNOUNCEMENT - CLOVER LAUNCHES COVID-19 BOOSTER VACCINE IN THE PEOPLE'S REPUBLIC OF CHINA
-
Feb 3, 2023Monthly Return of Equity Issuer on Movements in Securities for the Month ended January 31, 2023
-
Jan 16, 2023INSIDE INFORMATION - CLOVER PROVIDES UPDATES ON COVID-19 VACCINE COMMERCIAL LAUNCH AND STRATEGIC PRIORITIES IN 2023
-
Jan 4, 2023Monthly Return of Equity Issuer on Movements in Securities for the Month ended December 31, 2022
-
Dec 30, 2022Remuneration Committee - Terms of Reference
-
Dec 16, 2022(1) GRANT OF OPTIONS AND RSUS (2) AMENDMENT TO VESTING SCHEDULE OF PREVIOUSLY GRANTED RSUS AND (3) AMENDMENT TO THE TRUST DEED
-
Dec 13, 2022Next Day Disclosure Returns
-
Dec 13, 2022COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE
-
Dec 6, 2022PLACING OF NEW SHARES UNDER GENERAL MANDATE
-
Dec 5, 2022VOLUNTARY ANNOUNCEMENT - COVID-19 VACCINE (SCB-2019 (CPG 1018/ALUM)) INCLUDED FOR EMERGENCY USE IN THE PRC
-
Dec 2, 2022Monthly Return of Equity Issuer on Movements in Securities for the Month ended November 30, 2022
-
Nov 30, 2022VOLUNTARY ANNOUNCEMENT - CLOVER'S VACCINE CANDIDATE REDUCED HOUSEHOLD TRANSMISSION OF SARS-COV-2 BY 84% IN STUDY PUBLISHED IN CLINICAL INFECTIOUS DISEASES
-
Nov 3, 2022Monthly Return of Equity Issuer on Movements in Securities for the Month ended October 31, 2022
-
Oct 28, 2022LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
-
Oct 28, 2022RESIGNATION OF A NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE
-
Oct 14, 2022TERMINATION OF DISCLOSABLE TRANSACTION IN RELATION TO THE LEASE AGREEMENT
